
Grace Therapeutics, Inc. (GRCE) Stock Ticker
GRCE right now
Market factors today
Unlock the full GRCE picture
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE stock facts
| Ticker symbol | GRCE |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $34.5M |
| CEO | Prashant Kohli |
| Employees | 5 |
| Headquarters | Princeton, NJ, US |
| IPO date | 2012-02-07 |
| Website | www.gracetx.com |
What you can see for GRCE on Tickr
Live GRCE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GRCE report.
Rankings
FAQ
What is the ticker symbol for Grace Therapeutics, Inc.?
The ticker symbol for Grace Therapeutics, Inc. is GRCE, listed on the NASDAQ Global Market.
What is GRCE?
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal…